Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Abstract Background Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC).Giving look trail fusion pedals the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial.Here, we report a case of os